Hvivo

1. 22 Sep 26
   Directorate Change

   London, UK – 22 September 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, today announces the following changes to the Board as part of the ongoing...

   RNS 9783239 ↗
2. 15 Sep 26
   Half-year Results

   Contracted orderbook more than doubles in H1 2026

   RNS 9771744 ↗
3. 15 Sep 26
   SIGNAL 1 New CEO or CFO

   Richard Cotton appointed Interim CFO as permanent CFO search enters final stages

   Chief Financial Officer Succession · RNS 9771593 ↗
4. 27 Aug 26
   HVIVO acquires CRS Berlin

   London, UK - 27 August 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces the acquisition of CRS Clinical Research Services Berlin GmbH ("CRS Berlin").

   RNS 9742176 ↗
5. 27 Aug 26
   HVIVO acquires CRS Berlin, expanding expertise into dermatology and women's health markets

   London, UK – 27 August 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces the acquisition of CRS Clinical Research Services Berlin GmbH ("CRS Berlin").

   RNS 9742101 ↗
6. 23 Jul 26
   H1 2026 Trading Update

   Strong commercial momentum drives more than doubling of orderbook

   RNS 9682982 ↗
7. 13 Jul 26
   Change of Auditor

   London, UK - 13 July 2026, the board of hVIVO plc (AIM: HVO), a purpose built, full-service international clinical development partner and the world leader in human challenge trials, has agreed to appoint Grant Thornton UK LLP as its new auditor, following...

   RNS 9664250 ↗
8. 01 Jun 26
   Consultancy contract with Decoy Therapeutics

   Consultancy contract signed with Decoy Therapeutics to support development of respiratory antiviral candidates

   RNS 9595159 ↗
9. 20 May 26
   Capital Markets Day

   hVIVO to showcase integrated, full service early clinical development platform at Capital Markets Day

   RNS 9576569 ↗
10. 07 May 26
    £6m Influenza HCT contract signed

    £6m Influenza HCT contract signed with clinical-stage biopharmaceutical company

    RNS 9555884 ↗
11. 22 Apr 26
    HCT contract signed with ILiAD Biotechnologies

    hVIVO to conduct world's first pivotal Phase III human challenge

    RNS 9531473 ↗
12. 17 Apr 26
    Annual Report & Notice of AGM

    London, UK - 17 April 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, confirms that the Company's Annual Report and Accounts for the year ended 31 December...

    RNS 9524979 ↗
13. 15 Apr 26
    Final Results

    Integrated clinical development platform established following a year of strategic progress

    RNS 9520319 ↗
14. 14 Apr 26
    HVIVO launches unified brand identity

    hVIVO launches unified brand identity reflecting strategic transformation into integrated clinical development partner

    RNS 9518184 ↗
15. 14 Apr 26
    Influenza HCT contract signed with Traws Pharma

    London, UK - 14 April 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces that it has signed a Clinical Trial Agreement ("CTA") to conduct a human...

    RNS 9517963 ↗
16. 29 Jan 26
    Trading Update

    FY25 revenue in line and positive adjusted EBITDA

    RNS 9392530 ↗
17. 27 Jan 26
    Notice of Trading Update

    hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, confirms that it will issue a trading update for the year ended 31 December 2025 on Thursday 29 January 2026.

    RNS 9388098 ↗
18. 18 Dec 25
    Appointment of Non-Executive Director

    hVIVO strengthens Board with appointment of Richard Cotton as

    RNS 9304994 ↗
19. 15 Dec 25
    CEO & CFO Share Purchase

    hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that on 15 December 2025, Yamin 'Mo' Khan, Chief Executive Officer and Stephen Pinkerton, Chief...

    RNS 9297834 ↗
20. 27 Nov 25
    MSD to acquire Cidara

    MSD to acquire Cidara following Positive Results from Phase IIb Trial

    RNS 9260042 ↗
21. 20 Nov 25
    >£5 million CRS contracts signed

    hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces its German subsidiary CRS, has signed contracts worth over £5 million since September.

    RNS 9245433 ↗
22. 11 Nov 25
    Positive data from novel human challenge models

    Positive data from multiple novel human challenge models

    RNS 9225041 ↗
23. 03 Nov 25
    Presentation at Jefferies Healthcare Conference

    hVIVO to present at Jefferies Global Healthcare Conference

    RNS 9207520 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.